



Bone Marrow Failure in the Newborn Webinar

Internet Live Activity

Date: 11/03/2021

Time: 04:00 – 05:00 p.m. EDT

Location: Live Webinar (hosted via GoToWebinar)

Accreditation

The Mednax Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Mednax Center for Research, Education, Quality and Safety designates this Internet Live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Mednax Center for Research, Education, Quality and Safety is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The Mednax Center for Research, Education, Quality and Safety designates this Internet Live activity for a maximum of 1.00 *nursing contact hour(s)*. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

The Mednax Center for Research, Education, Quality and Safety adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies within the 24 months prior to their involvement with the CE activity. All relevant financial relationships listed have been mitigated prior to the commencement of the activity. Beyond disclosure of financial relationships, faculty are required to disclose when they plan to discuss pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

Disclosure of Financial Relationships

Akiko Shimamura, MD, PhD, faculty for this educational activity, is an Advisory/Review Committee Member for Novartis AG. *FDA Disclosures: none reported. All of the relevant financial relationships listed have been mitigated.*

Timothy Biela, MD, Nicole Brenson, Vicki Leamy, DNP, NNP-BC, planners of this educational activity, have no relevant financial relationships with ineligible companies to disclose.

Commercial Support

There is no commercial support for this educational activity.

Overview

The inherited bone marrow failure syndromes (IBMFS) are undoubtedly underdiagnosed, in both pediatric and adult hematology/oncology practices. The inherited marrow failure syndromes are a diverse set of genetic disorders characterized by hematopoietic aplasia and cancer predisposition. The clinical phenotypes are highly variable and much broader than previously recognized. Early recognition of these disorders allows for appropriate medical management and surveillance. This presentation will address identification of infants who would benefit from evaluation for a genetic bone marrow failure condition. In addition, features of genetic bone marrow failure conditions in the newborn will be reviewed.

Objectives

At the conclusion of this activity, the participant will be able to:

1. Understand the rationale for early diagnosis of a genetic bone marrow failure condition.
2. Recognize clinical features associated with genetic bone marrow failure conditions.

ACGME/ABMS Competencies

- Medical Knowledge

IOM Competencies

- Work in interdisciplinary teams
- Employ evidence-based practice

Evaluation, Attendance and Credit

Within <https://mednax.cloud-cme.com>, click My CE and then select Evaluations and Certificates. Follow the instructions to record attendance/time spent and complete the brief evaluation. You will have the option to email the certificate of attendance to your mailbox.